WO1992017173A2 - Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme - Google Patents
Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme Download PDFInfo
- Publication number
- WO1992017173A2 WO1992017173A2 PCT/FR1992/000296 FR9200296W WO9217173A2 WO 1992017173 A2 WO1992017173 A2 WO 1992017173A2 FR 9200296 W FR9200296 W FR 9200296W WO 9217173 A2 WO9217173 A2 WO 9217173A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- riboflavin
- vitamin
- herpes
- malaria
- preventive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4508599A JPH06506212A (ja) | 1991-04-02 | 1992-04-02 | Hivウイルス系疾病、ヘルペス、色素性網膜炎およびマラリアの治療向けリボフラビンの利用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9104218A FR2674753B1 (fr) | 1991-04-02 | 1991-04-02 | Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. |
FR91/04218 | 1991-04-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1992017173A2 true WO1992017173A2 (fr) | 1992-10-15 |
WO1992017173A3 WO1992017173A3 (fr) | 1993-01-07 |
Family
ID=9411559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1992/000296 WO1992017173A2 (fr) | 1991-04-02 | 1992-04-02 | Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0578733A1 (fr) |
JP (1) | JPH06506212A (fr) |
AU (1) | AU1654092A (fr) |
CA (1) | CA2107078A1 (fr) |
FR (1) | FR2674753B1 (fr) |
OA (1) | OA09819A (fr) |
WO (1) | WO1992017173A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2696319A1 (fr) * | 1992-10-02 | 1994-04-08 | Berque Jean | Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux. |
EP0643775A1 (fr) * | 1992-05-28 | 1995-03-22 | Monash University | Compositions therapeutiques |
WO1995011028A1 (fr) * | 1993-10-19 | 1995-04-27 | Radopath Limited | Derives de flavine utilises comme agents antiviraux |
US5730971A (en) * | 1993-12-27 | 1998-03-24 | Sanwa Kagaku Kenkyusho Co., Ltd. | Potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator |
GB2319474A (en) * | 1993-10-19 | 1998-05-27 | Radopath Ltd | Anti-viral agents |
WO2002074313A1 (fr) * | 2001-03-21 | 2002-09-26 | Eisai Co., Ltd. | Médicaments à base de vitamine b2 réduite |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ244270A (en) * | 1991-09-13 | 1995-07-26 | Eisai Co Ltd | Injectable composition comprising riboflavin |
US6277337B1 (en) | 1998-07-21 | 2001-08-21 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
US6258577B1 (en) | 1998-07-21 | 2001-07-10 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using endogenous alloxazine or isoalloxazine photosensitizers |
US6268120B1 (en) | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
US7985588B2 (en) | 2000-06-02 | 2011-07-26 | Caridianbct Biotechnologies, Llc | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light |
TW590780B (en) | 2000-06-02 | 2004-06-11 | Gambro Inc | Additive solutions containing riboflavin |
US7648699B2 (en) | 2000-06-02 | 2010-01-19 | Caridianbct Biotechnologies, Llc | Preventing transfusion related complications in a recipient of a blood transfusion |
US6548241B1 (en) | 2000-11-28 | 2003-04-15 | Gambro, Inc. | Storage solution containing photosensitizer for inactivation of biological contaminants |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2096712A1 (en) * | 1970-06-29 | 1972-02-25 | Giraux Georges | Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders |
GB1431841A (en) * | 1973-01-15 | 1976-04-14 | Evans S C | Ophthalmic-nutritional preparations |
JPS59172417A (ja) * | 1983-03-23 | 1984-09-29 | Nisshin Kagaku Kk | リボフラビン酪酸エステル含有軟カプセル |
EP0196515A1 (fr) * | 1985-03-14 | 1986-10-08 | Baxter Travenol Laboratories, Inc. | Inactivation photodynamique de virus dans des compositions thérapeutiques contenant des protéines |
DE3542309A1 (de) * | 1985-11-29 | 1987-06-04 | Cardona Federico Dr | Medizinisches antioxidativum |
WO1991004744A1 (fr) * | 1989-10-06 | 1991-04-18 | The Beth Israel Hospital Association | Procede et appareil de traitement d'etats pathologiques a l'aide de lipoproteines oxydees |
WO1991007168A1 (fr) * | 1989-11-09 | 1991-05-30 | Schering-Plough Healthcare Products, Inc. | Riboflavine comme promoteur du tannage |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2559569A1 (de) * | 1975-10-22 | 1977-04-28 | Josef Hofmann | Fluessiges futtermittel fuer brieftauben |
US4500524A (en) * | 1982-09-15 | 1985-02-19 | Trustees Of Boston University | Tranquilizing and reducing or preventing seizures |
-
1991
- 1991-04-02 FR FR9104218A patent/FR2674753B1/fr not_active Expired - Fee Related
-
1992
- 1992-04-02 WO PCT/FR1992/000296 patent/WO1992017173A2/fr not_active Application Discontinuation
- 1992-04-02 CA CA002107078A patent/CA2107078A1/fr not_active Abandoned
- 1992-04-02 JP JP4508599A patent/JPH06506212A/ja active Pending
- 1992-04-02 AU AU16540/92A patent/AU1654092A/en not_active Abandoned
- 1992-04-02 EP EP92909405A patent/EP0578733A1/fr not_active Withdrawn
-
1993
- 1993-10-01 OA OA60422A patent/OA09819A/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2096712A1 (en) * | 1970-06-29 | 1972-02-25 | Giraux Georges | Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders |
GB1431841A (en) * | 1973-01-15 | 1976-04-14 | Evans S C | Ophthalmic-nutritional preparations |
JPS59172417A (ja) * | 1983-03-23 | 1984-09-29 | Nisshin Kagaku Kk | リボフラビン酪酸エステル含有軟カプセル |
EP0196515A1 (fr) * | 1985-03-14 | 1986-10-08 | Baxter Travenol Laboratories, Inc. | Inactivation photodynamique de virus dans des compositions thérapeutiques contenant des protéines |
DE3542309A1 (de) * | 1985-11-29 | 1987-06-04 | Cardona Federico Dr | Medizinisches antioxidativum |
WO1991004744A1 (fr) * | 1989-10-06 | 1991-04-18 | The Beth Israel Hospital Association | Procede et appareil de traitement d'etats pathologiques a l'aide de lipoproteines oxydees |
WO1991007168A1 (fr) * | 1989-11-09 | 1991-05-30 | Schering-Plough Healthcare Products, Inc. | Riboflavine comme promoteur du tannage |
Non-Patent Citations (19)
Title |
---|
Annali di Ottalmologia e Clinica Oculistica, vol. 94, no. 8, août 1968, R. CUPPINI et al.: "Terapia lattoflavinica della cheratite erpetica", pages 926-928, voir le document en entier * |
Annals of the New York Academy of Sciences, vol. 587, 1990, J.D. BOGDEN et al.: "Micronutrient status and human immunodeficiency virus (HIV) infection", pages 189-195, voir le document en entier * |
Japanese Journal of Ophthalmology, vol. 21, no. 3, 1977, Y. TANO et al.: "Photodynamic inactivation of herpes simplex virus", pages 392-398, voir le document en entier, surtout tableau 1 * |
Korea Univ. Med. J., vol. 16, no. 1, 1979, J.P. KIM: "A study on the effect of hibon (riboflavin tetrabutyrate) on arteriosclerotic retinopathy, diabetic retinopathy and cataract", pages 299-306, voir le document en entier * |
Osaka Kyoiku Daigaku Kiyo, Dai-3-Bumon, vol. 28, nos. 2-3, 1980, S. FUJISHITA et al.: "Identification of flavin derivatives contained in the frog retina and pigment layer", pages 135-139, voir le document en entier * |
Osaka Kyoiku Daigaku Kiyo, vol. 35, no. 1, août 1986, S. FUJISHITA et al.: "The quantitative relation between the riboflavin in the choroid and the rhodopsin in the retina", pages 123-128, voir le document en entier * |
Patent Abstracts of Japan, vol. 9, no. 21 (C-263), 29 janvier 1985, & JP,A,59172417 (NITSUSHIN KAGAKU K.K.) 29 septembre 1984, voir résumé en entier * |
Photochemistry and Photobiology, vol. 24, no. 3, septembre 1976, Pergamon Press, (GB), O.M. PEREIRA et al.: "Photosensitization of human diploid cell cultures by intracellular flavins and protection by antioxidants", pages 237-242, voir le document en e ntier * |
R. BERKOW et al.: "The Merck Manual of Diagnosis and Therapy", 15 édition, 1987, Merck & Co., Inc., Rahway, NJ, US, voir page 2234: "Retinitis pigmentosa" * |
The American Journal of Clinical Nutrition, vol. 51, no. 5, mai 1990, American Society for Clinical Nutrition, B.S. DAS et al.: "Increased plasma lipid peroxidation in riboflavin-deficient malaria-infected children1-3", pages 859-863, voir le document en entier * |
The American Journal of Tropical Medicine and Hygiene, vol. 37, no. 3, novembre 1987, The American Society of Tropical Medicine and Hygiene, W.B. COWDEN et al.: "Antimalarial activity of a riboflavin analog against Plasmodium vinckei in vivo and Plasmodium falciparum in vitro", pages 495-500, voir le document en entier * |
The FASEB Journal, vol. 3, no. 3, 9 février 1989, E. MANTERO-ATIENZA et al.: "Nutritional status of a cohort of HIV-1 positive gay men", voir page A657, résumé no. 2502, voir résumé en entier * |
The Journal of Investigative Dermatology, vol. 58, no. 4, avril 1972, (US), D. ROTH et al.: "Protective action of flavins on ultraviolet irradiated DNA", pages 233-237, voir le document en entier * |
The Journal of Investigative Dermatology, vol. 65, no. 6, décembre 1975, L.J. PACERNICK et al.: "The inefficacy of riboflavin against ultraviolet-induced carcinogenesis", pages 547-548, voir le document en entier * |
The Journal of Nutrition, vol. 117, no. 1, janvier 1987, C.D. ECKHERT: "Differential effects of riboflavin and RRR-alpha-tocopheryl acetate on the survival of newborn RCS rats with inheritable retinal degeneration", pages 208-211, voir le document en entier * |
The Journal of Protozoology, vol. 32, no. 1, février 1985, The Society of Protozoologists, T.G. GEARY et al.: "Nutritional requirements of Plasmodium falciparum in culture. II. Effects of antimetabolites in a semi-defined medium", pages 65-69, voir le document en entier * |
The Lancet, vol. 2, no. 8463, 9 novembre 1985, P. DUTTA et al.: "Antimalarial effects of riboflavin deficiency", pages 1040-1043, voir le document en entier * |
Vestn. Oftal. (USSR), vol. 3, 1974, G.A. VINKOVA: "Riboflavin and ascorbic acid in a diseased healthy cornea", pages 39-40, voir résumé anglais * |
Vestn. Oftamol., vol. 6, novembre-décembre 1978, L.A. KATSNELSON et al.: "Experience of treating with the drug fad (elavin-adeninenucleotide) of central tapeto-retinal abiotrophies", pages 63-67, voir le document en entier * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0643775A4 (fr) * | 1992-05-28 | 1995-12-27 | Univ Monash | Compositions therapeutiques. |
EP0643775A1 (fr) * | 1992-05-28 | 1995-03-22 | Monash University | Compositions therapeutiques |
US5981601A (en) * | 1992-05-28 | 1999-11-09 | Centre For Molecular Biology And Medicine | Method for enhancing cellular bioenergy |
WO1994007499A1 (fr) * | 1992-10-02 | 1994-04-14 | Jean Berque | Utilisation de derives de la flavine pour la realisation d'articles d'hygiene medico-chirurgicaux et les articles d'hygiene ainsi realises |
FR2696319A1 (fr) * | 1992-10-02 | 1994-04-08 | Berque Jean | Utilisation de produits biologiques atoxiques et principalement de la riboflavine dans la fabrication des préservatifs et des gants de protection médico-chirurgicaux. |
WO1995011028A1 (fr) * | 1993-10-19 | 1995-04-27 | Radopath Limited | Derives de flavine utilises comme agents antiviraux |
AP620A (en) * | 1993-10-19 | 1997-10-14 | Radopath Ltd | Uses of a flavin in the treatment of ill-effects caused by viral infections. |
GB2319474A (en) * | 1993-10-19 | 1998-05-27 | Radopath Ltd | Anti-viral agents |
GB2283913A (en) * | 1993-10-19 | 1995-05-24 | Radopath Ltd | Anti-viral agents comprising flavins |
US5730971A (en) * | 1993-12-27 | 1998-03-24 | Sanwa Kagaku Kenkyusho Co., Ltd. | Potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator |
US9044523B2 (en) | 2000-06-15 | 2015-06-02 | Terumo Bct, Inc. | Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light |
WO2002074313A1 (fr) * | 2001-03-21 | 2002-09-26 | Eisai Co., Ltd. | Médicaments à base de vitamine b2 réduite |
US7579325B2 (en) | 2001-03-21 | 2009-08-25 | Eisai R & D Management Co., Ltd. | Drugs containing reduced of vitamin B2 |
Also Published As
Publication number | Publication date |
---|---|
FR2674753A1 (fr) | 1992-10-09 |
OA09819A (fr) | 1994-04-15 |
AU1654092A (en) | 1992-11-02 |
CA2107078A1 (fr) | 1992-10-03 |
JPH06506212A (ja) | 1994-07-14 |
EP0578733A1 (fr) | 1994-01-19 |
WO1992017173A3 (fr) | 1993-01-07 |
FR2674753B1 (fr) | 1995-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5945106A (en) | Montoxic extract of Larrea tridentata and method of making the same | |
WO1992017173A2 (fr) | Utilisation de la riboflavine dans le traitement de maladies liees aux virus hiv, de l'herpes, de la retinite pigmentaire et du paludisme | |
NL192914C (nl) | Werkwijze voor de bereiding van een antioxidant preparaat en daarmee verkregen preparaat. | |
EP0732927B1 (fr) | Compositions d'entre autres la riboflavine pour la protection locale des muqueuses genitales et rectales | |
US20060068043A1 (en) | Composition for treating chronic venous insufficiencies using an extract of red vine leaves | |
EP0352147A2 (fr) | Utilisation de la Naringine, de la Naringénine ou leurs dérivés pour faire une composition pharmaceutique anticancéreuse | |
US20120009278A1 (en) | Composition To Retard the Onset of Symptoms of Alzheimer's Disease | |
FR2715303A1 (fr) | Utilisation du FAD et/ou du NAD comme médicaments. | |
EP0225831B1 (fr) | Utilisation d'huiles hyperoxygénées pour la fabrication d'un médicament pour le traitement de l'herpès. | |
CZ290794A3 (en) | Antemetic composition | |
EP2274000B1 (fr) | Composition pharmaceutique ou dietetique comprenant des extraits aqueux de nigella sativa et d'olea europea et/ou phyllantus amarus | |
EP0722325B1 (fr) | Composition pour le traitement ou la prevention de l'herpes | |
WO2021099453A1 (fr) | Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes | |
US20050182037A1 (en) | Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof | |
EP0502765B1 (fr) | Nouvelles compositions diététiques à base de lipides complexes phosphorés et leur utilisation dans les troubles du sommeil | |
US7358278B2 (en) | Cellular phosphorylation potential enhancing compositions preparation and use thereof | |
EP0402208A1 (fr) | Association de vitamine A à dose physiologique et de différents principes actifs ayant une activité thérapeutique | |
WO1994007499A1 (fr) | Utilisation de derives de la flavine pour la realisation d'articles d'hygiene medico-chirurgicaux et les articles d'hygiene ainsi realises | |
US20090156649A1 (en) | Cellular phosphorylation potential enhancing compositions preparation and use thereof | |
FR3111541A1 (fr) | Extrait d'un champignon de la famille des BOLETUS FUNGI pour son utilisation notamment dans la prévention de la maladie Covid 19 | |
CA2181885A1 (fr) | Solution injectable de fluorure de benzalkonium | |
RU2182823C1 (ru) | Способ лечения больных псориазом в сочетании с хроническим описторхозом | |
RU2203677C1 (ru) | Эликсир для лечения заболеваний желудочно-кишечного тракта, нормализующий обмен веществ и обладающий седативным действием | |
WO2022091023A1 (fr) | Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire | |
BE1000256A6 (fr) | Composition pour le traitement de la peau, des cheveux et des ongles, son procede de preparation et son utilisation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR CA CS FI HU JP NO PL RO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: PL |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR CA CS FI HU JP NO PL RO RU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992909405 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2107078 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1992909405 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 129051 Country of ref document: US Date of ref document: 19940210 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992909405 Country of ref document: EP |